Drug Profile

Recombinant birch pollen allergoid - Allergopharma

Alternative Names: Bet v 1 - Allergopharma; Betv1; Recombinant birch pollen

Latest Information Update: 05 Apr 2013

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Allergopharma
Class Allergens; Peptide vaccines; Peptides; Skin disorder therapies; Tree pollen allergy immunotherapies
Mechanism of Action Immunomodulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No

05 Apr 2013 No development reported - Phase-III for Seasonal allergic rhinitis in Germany (Parenteral)
24 Aug 2010 Phase III development is ongoing in Germany
01 Jun 2009 Allergopharma completes a Phase-III trial in Seasonal allergic rhinitis in Germany (NCT00309062)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com